Abstract: Table of Content: Volume 4, Issue 1 Select All | | Research Article Pages 58-68 Patterns of Care and Predictors of Survival among DCIS Patients: An NCDB Analysis Authors: Justine S Broecker, Yuan S Liu, Betsey Dewey, Toncred Styblo and Theresa S Gillespie Abstract: The National Cancer Database (NCDB) was queried to identify all patients diagnosed with DCIS between 2004- 2015. After applying exclusion criteria, Cox proportional hazards and Kaplan-Meier analysis were performed to compare treatment groups and estimate risk of death stratified by demographics, clinical features, and treatment delivered. An average treatment effect (ATE) was calculated between three matched treatment cohorts of interest: Lumpectomy alone, extended local therapy (lumpectomy/radiation or mastectomy) and extended local therapy + anti-hormonal therapy. | | | Original Article Pages 48-57 Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer Authors: Gagan Gupta, MS, Caroline Dasom Lee, MD, Mary L Guye, MD, FACS, Robert E Van Sciver, PhD, Michael P Lee, MD, Alex C Lafever, MD, Anthony Pang, BS, Angela M Tang-Tan, BS, Janet S Winston, MD, Billur Samli, MD, Rick J Jansen, PhD, Richard A Hoefer, DO, FACS and Amy H Tang, PhD Abstract: Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard firstline treatment for most women diagnosed with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer. Current clinical prognostic tools evaluate four clinicopathological factors: Tumor size, LN status, pathological stage, and tumor molecular subtype. However, many similarly treated patients with identical residual cancer burden (RCB) following NACT experience distinctly different tumor relapse rates, clinical outcomes and survival. | | | Case Report Pages 44-47 Difficult-to-Diagnose Hormone-Negative, Human Epidermal Growth Factor Receptor 2-Positive Poorly-Differentiated Breast Cancer in a Male Patient Authors: Masahiro Kitada, MD, Shunsuke Yasuda, MD, Masahiro Abe, MD, Nana Yoshida, MD, Satoshi Okazaki, MD and Kei Ishibashi, MD Abstract: A 67-year-old man working in Southeast Asia presented for evaluation. The patient had visited a different hospital with general malaise and rapid weight loss. CT and MRI showed a giant mediastinal tumor and enlarged lymph nodes in the neck and thoracic cavity. The patient returned to Japan and visited our hospital. He was 165 cm in height and weighed 51 kg. Edema of the upper body, including swelling of the neck was observed, and subcutaneous thickening and mass formation were observed in the left chest. | | |
Publication Year: 2020
Publication Date: 2020-10-01
Language: en
Type: paratext
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot